---
company: MapLight Therapeutics, Inc.
ticker: MPLT
form: 8-K
filed: 2026-08-13
accession: 0001193125-26-349490
source: https://www.sec.gov/Archives/edgar/data/1770069/000119312526349490/
---

# MapLight Therapeutics (MPLT) earnings release, August 13, 2026

MapLight Therapeutics, Inc. (MPLT) · Form 8-K, Item 2.02 · Filed 2026-08-13 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1770069/000119312526349490/)

Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of

ML-007C-MA in schizophrenia, supporting advancement into a Phase 3

ZEPHYR-2 trial

Continued advancement of

ML-007C-MA in ADP, with enrollment ongoing in the Phase 2 VISTA trial and topline results expected in the second half of 2027

Reported Phase 2 IRIS results for

ML-004 in autism spectrum disorder, with clinically meaningful improvements in irritability observed in a prespecified adolescent subgroup

Primarily focusing resources on the advancement of

ML-007C-MA

Ended the quarter with

$351.3 million in cash, cash equivalents and investments, which, together with the Company’s recent $150 million private placement, is expected to extend cash runway through 2028, including through the projected readouts for both

VISTA and

ZEPHYR-2

SAN FRANCISCO and BOSTON, August 13, 2026 (GLOBE

NEWSWIRE) — MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.

“With positive Phase 2 data from ZEPHYR and continued progress in VISTA, we are focusing our efforts on advancing

ML-007C-MA in both schizophrenia and ADP,” said Chris Kroeger,

Co-Founder and Chief Executive Officer of MapLight. “In schizophrenia, ZEPHYR met its primary endpoint and achieved meaningful efficacy results, an encouraging cognitive signal and a tolerability profile designed to translate into real-world use, supporting our planned registrational Phase 3

ZEPHYR-2 trial. In ADP, enrollment in VISTA remains ongoing, with topline results expected in the second half of 2027.

Together with our recent private placement and continued focus on capital discipline, we believe we are well positioned to execute on both programs through these key milestones.”

Business Update and Upcoming Milestones

ML-007C-MA

(M¹

/M⁴

Muscarinic Agonist) for the Treatment of

Schizophrenia

ML-007C-MA for the

Treatment of Alzheimer’s Disease Psychosis (ADP)

ML-004

(5-HT

1B/1D

Agonist) for the Treatment of Autism Spectrum Disorder (ASD)

Corporate Updates

Second Quarter 2026 Financial Results

About MapLight Therapeutics

MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. The Company was founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The Company’s discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.

For more information, please visit www.maplightrx.com.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, the clinical development and potential benefits of

ML-007C-MA and

ML-004, the design, timing and conducting of future clinical trials, the registrational pathway for the Company’s product candidates, including holding EOP2 meetings with the FDA for

ML-007C-MA and

ML-004 and planned regulatory submissions, the availability and timing of results from the Company’s Phase 2 VISTA trial and the Company’s Phase 3

ZEPHYR-2 trial, and the potential benefits of the Company’s discovery platform. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,”

“can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, are intended to identify forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in the Company’s filings with the U.S. Securities and Exchange Commission (SEC)), many of which are beyond the Company’s control and subject to change. Actual results could be materially different. Risks and uncertainties include: the unpredictable relationship between preclinical study results and clinical study results; the risk that results obtained in any clinical trials to date may not be indicative of results obtained in ongoing or future trials; the timing or likelihood of regulatory filings and approvals; expectations regarding the Company’s ability to fund its current operations; and other risks and uncertainties identified in the Company’s Quarterly Report on Form

10-Q for the quarter ended June 30, 2026, and subsequent disclosure documents the Company may file with the SEC. The Company claims the protection of the safe harbor contained in the Private Securities

Litigation Reform Act of 1995 for forward-looking statements. The Company expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

MapLight Therapeutics, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

(in thousands, except share and per share amounts)

Select Condensed Consolidated Balance Sheet Data

(Unaudited)

(in thousands)

For investor inquiries: investors@maplightrx.com

For media inquiries: media@maplightrx.com

## Financial statements

### Income Statement (Three Months Ended June 30, — (in thousands, except share and per share amounts))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Operating expenses: | Research and development | 53,435 | 26,846 | 107,119 | 46,633 |
| Operating expenses: | General and administrative | 10,113 | 3,817 | 20,932 | 7,573 |
| Operating expenses: | Total operating expenses | 63,548 | 30,663 | 128,051 | 54,206 |
| Operating expenses: | Loss from operations | -63,548 | -30,663 | -128,051 | -54,206 |
| Other income, net: | Interest income | 2,349 | 688 | 4,821 | 1,499 |
| Other income, net: | Other income, net | 1,007 | 130 | 2,370 | 522 |
| Other income, net: | Net loss | -60,192 | -29,845 | -120,860 | -52,185 |
| Other income, net: | Net loss per share - basic and diluted | -1.32 | -39.11 | -2.66 | -68.46 |
| Other income, net: | Weighted-average number of common shares outstanding - basic and diluted | 45,431,359 | 763,044 | 45,354,488 | 762,325 |

### Balance Sheet (June 30, 2026 — (in thousands))

| | June 30, 2026 | December 31, 2025 |
|---|---:|---:|
| Cash, cash equivalents and investments | 351,341 | 453,096 |
| Total assets | 368,348 | 479,512 |
| Total current liabilities | 19,294 | 16,229 |
| Total liabilities | 20,049 | 21,140 |
| Total stockholders’ equity | 348,299 | 458,372 |
